Talphera - Forum WKN: A3DWPN ISIN: US00444T2096 Kürzel: TLPH Forum: Aktien User: Summer.76

.

Talphera Price Target Raised to $6.00/Share From $5.00 by HC Wainwright & Co. https://www.benzinga.com/quote/TLPH/analyst-ratings

Wow. Vielen Dank für die Information. Hab mich schon gefragt was plötzlich los ist. Das sind sehr gute Nachrichten. 👍

https://www.prnewswire.com/news-releases/talphera-announces-26-million-capital-commitment-through-a-combination-of-a-non-dilutive-royalty-monetization-and-equity-offering-302037920.html

Mal schauen wie es hier weiterläuft

AcelRx Announces Rebranding With Name Change to Talphera, Inc. https://www.prnewswire.com/news-releases/acelrx-announces-rebranding-with-name-change-to-talphera-inc-302029288.html Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on Nasdaq under the trading symbol "TLPH" effective January 10 ...

https://www.acelrx.com/news-releases/news-release-details/acelrx-pharmaceuticals-announces-publication-study-evaluating

https://www.prnewswire.com/news-releases/acelrx-reports-third-quarter-2023-financial-results-and-provides-corporate-update-301982149.html

https://www.publicnow.com/view/0366A8A3183E37725CF7D9F410DD0FB45637F347 ...On September 22, 2023, the FDA notified the Company that due to the volume of EUA requests the FDA has received, the FDA has determined that review of the Niyad EUA is not a priority and has therefore declined to issue an EUA for Niyad at this time pursuant to the FDA's current prioritization of EUA requests. In the notice letter, the FDA encouraged the Company to continue to assess clinical development of the Niyad device. The Company plans to initiate a registrational study of Niyad later this year and anticipates submitting a Pre-Market Application ("PMA") for Niyad to the FDA in 2024. ....

...und alle Jahre wieder... Bestimmt ein Dauerauftrag 🤭

Dem ist glaub langweilig Kauft halt 10000 stk. 😁

Insider Buying: CEO Vincent Angotti Acquires 10,000 Shares of AcelRx Pharmaceuticals Inc https://www.gurufocus.com/news/2083853/insider-buying-ceo-vincent-angotti-acquires-10000-shares-of-acelrx-pharmaceuticals-inc

HC Wainwright Upgrades AcelRx Pharmaceuticals to Buy From Neutral, Price Target is $8 https://www.marketscreener.com/quote/stock/ACELRX-PHARMACEUTICALS-I-7314079/news/HC-Wainwright-Upgrades-AcelRx-Pharmaceuticals-to-Buy-From-Neutral-Price-Target-is-8-44649944/ Na dann 🙃

AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update https://www.prnewswire.com/news-releases/acelrx-reports-second-quarter-2023-financial-results-and-provides-corporate-update-301897581.html Capital raise closed in July, led by new healthcare investors; provides access to up to $26.3 million in capital, with $10 million immediately available AcelRx awaits response to Emergency Use Authorization (EUA) of Niyad™ submitted to the FDA in April; registrational study set to initiate in Q4 2023 Proforma $17.4 million in cash as of June 30, 2023, including gross proceeds from financing closed in July 2023 Senior debt with Oxford fully repaid in Q2 2023

AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rules https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-closing-of-previously-announced-private-placement-priced-at-the-market-under-nasdaq-rules-301882640.html Transformative capital raise, led by new investors including Nantahala Capital Management   The private placement provides access to up to $26.3 million of gross proceeds upon the exercise of the milestone-affected warrants

AcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-10-million-private-placement-of-securities-priced-at-the-market-under-nasdaq-rules-301879430.html Upon the achievement of certain milestones accelerating the warrants' expiration date, AcelRx may receive an additional $16.3 million of gross proceeds if the common warrants are exercised in full